Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
Sponsor: Icahn School of Medicine at Mount Sinai
Listed as NCT00552188, this PHASE2 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by Icahn School of Medicine at Mount Sinai, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Icahn School of Medicine at Mount Sinai
- Massachusetts General Hospital
- Montreal Heart Institute
- Tallikut Pharmaceuticals, Inc.
- University of Massachusetts, Worcester
- Winthrop University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .